Drug-Drug Interaction Study of ABP-671 in Gout Patients
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorAtom Therapeutics Co., Ltd
About this trial
This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.
Eligibility criteria
Qualifiers
Adults 18-75 years with clinical diagnosis of gout.
Stable Allopurinol therapy QD for ≥14 days prior to Day 1.
Cohort N: Normal renal function.
Cohort R: Moderate renal impairment.
Disqualifiers
Clinically significant hepatic impairment.
History of Allopurinol hypersensitivity.
Pregnancy or breastfeeding.
Trial design
Treatments tested in this trial
- ABP-671 plus allopurinol
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov